pertuzumab

GPTKB entity

Statements (63)
Predicate Object
gptkbp:instance_of gptkb:monoclonal_antibody
gptkbp:administered_by intravenous infusion
chemotherapy
gptkbp:approves gptkb:2012
gptkb:European_Union
gptkb:FDA
gptkb:United_States
gptkbp:can_be_combined_with gptkb:trastuzumab
gptkbp:chemical_formula C6460 H9932 N1716 O1980 S44
gptkbp:clinical_trial gptkb:APHINITY_trial
gptkb:CLEOPATRA_trial
gptkb:NEOSPHERE_trial
Phase III
gptkbp:clinical_use adjuvant therapy
neoadjuvant therapy
metastatic breast cancer
gptkbp:contraindication pregnancy
lactation
hypersensitivity to pertuzumab
gptkbp:developed_by gptkb:Genentech
gptkbp:dosing loading dose followed by maintenance dose
https://www.w3.org/2000/01/rdf-schema#label pertuzumab
gptkbp:indication gptkb:HER2-positive_breast_cancer
gptkbp:interacts_with other HER2-targeted therapies
gptkbp:invention patented
gptkbp:is_monitored_by cardiac function
gptkbp:knockouts high
gptkbp:marketed_as gptkb:Perjeta
gptkbp:mechanism_of_action HER2 receptor blockade
gptkbp:pharmacokinetics long half-life
inhibition of HER2 signaling
gptkbp:produced_by recombinant DNA technology
gptkbp:provides_guidance_on ASCO guidelines
NCCN guidelines
gptkbp:research other cancers
gptkbp:research_focus combination therapies
biomarker studies
resistance mechanisms
patient selection
gptkbp:route_of_administration IV
gptkbp:safety_features generally well tolerated
gptkbp:service_frequency every 3 weeks
gptkbp:shelf_life 24 months
gptkbp:side_effect gptkb:anemia
fatigue
nausea
diarrhea
peripheral neuropathy
thrombocytopenia
infusion reactions
neutropenia
hypersensitivity reactions
cardiac dysfunction
gptkbp:storage refrigerated
gptkbp:targets gptkb:HER2
gptkbp:treatment with trastuzumab and docetaxel
gptkbp:type humanized monoclonal antibody
gptkbp:used_for gptkb:Oncology
gptkbp:website IV site
gptkbp:weight 148 k Da
gptkbp:bfsParent gptkb:Perjeta
gptkb:Herceptin
gptkbp:bfsLayer 5